secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056934
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports Q1 net loss $10.3M; neffy PDUFA date Oct 2, 2024; cash $223.6M
--------------------------------------------------------------------------------

- Cash and securities $223.6M as of March 31, 2024; expected operating runway at least three years.
- Net loss $10.3M for Q1 2024 compared to $15.0M in Q1 2023; R&D expenses $5.2M, G&A $8.0M.
- FDA PDUFA target date for neffy NDA is October 2, 2024; CRL response submitted April 2.
- European CHMP opinion on neffy MAA expected in Q2 2024; Day 180 response submitted April 30.
- Exclusive license agreement with CSL Seqirus for Australia and New Zealand; up to $5M in payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/0000950170-24-056934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/spry-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer